REBEL Core Cast 8.0 – The NEJM + Non-Inferiority Studies

Take Home Points on Non-Inferiority Studies

  • Non-inferiority studies should be done when a new treatment (or diagnostic modality) requires less resources (cost or time), is easier for the patient or has a lower side-effect profile.
  • Non-inferiority study design largely negates the protections against bias added by blinding and randomization.
  • Non-inferiority studies can be used to manipulate clinicians when a superiority study would be more appropriate.

REBEL Core Cast 8.0 – The NEJM + Non-Inferiority Studies

Click here for Direct Download of Podcast



  1. Stets R et al. Omadacycline for Community-Acquired Bacterial Pneumonia. NEJM 2019; 380(6): 511-27. PMID: 30726692
  2. O’Riordan W et al. Omadacycline for Acute Bacterial Skin and Skin-Structure Infections. NEJM 2019; 380(6): 528-38. PMID: 30726689
  3. Lundh A et al. Industry sponsorship and research outcome: systematic review with meta-analysis. Intensive Care Med 2018; 44(10): 1603-12. PMID: 30132025

Show Notes Written By: Miguel Reyes, MD (Twitter: @Miguel_ReyesMD)

Post Peer Reviewed By: Salim R. Rezaie, MD (Twitter: @srrezaie)

Cite this article as: Anand Swaminathan, "REBEL Core Cast 8.0 – The NEJM + Non-Inferiority Studies", REBEL EM blog, April 3, 2019. Available at:

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share via Email

Want to support rebelem?